share_log

Cybin | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Cybin | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Cybin | 6-K:外国发行人报告
SEC announcement ·  04/10 17:28
Moomoo AI 已提取核心信息
Cybin Inc., a clinical-stage biopharmaceutical company, has announced that its CEO, Doug Drysdale, will present at the Bloom Burton & Co. Healthcare Investor Conference on April 16, 2024. The conference will be held in Toronto, Ontario, and Drysdale's presentation is scheduled to be webcast live at 1:30 p.m. ET. Cybin, known for developing innovative psychedelic treatment options for mental health conditions, is currently working on CYB003, a treatment for major depressive disorder, and CYB004 for generalized anxiety disorder. The company, which was founded in 2019, operates in multiple countries and continues to focus on advancing its proprietary drug discovery platforms and treatment regimens.
Cybin Inc., a clinical-stage biopharmaceutical company, has announced that its CEO, Doug Drysdale, will present at the Bloom Burton & Co. Healthcare Investor Conference on April 16, 2024. The conference will be held in Toronto, Ontario, and Drysdale's presentation is scheduled to be webcast live at 1:30 p.m. ET. Cybin, known for developing innovative psychedelic treatment options for mental health conditions, is currently working on CYB003, a treatment for major depressive disorder, and CYB004 for generalized anxiety disorder. The company, which was founded in 2019, operates in multiple countries and continues to focus on advancing its proprietary drug discovery platforms and treatment regimens.
临床阶段的生物制药公司Cybin Inc. 宣布,其首席执行官道格·德赖斯代尔将出席布鲁姆·伯顿公司。2024年4月16日的医疗保健投资者大会。会议将在安大略省多伦多举行,德赖斯代尔的演讲定于美国东部时间下午 1:30 进行网络直播。Cybin 以开发针对心理健康状况的创新迷幻治疗方案而闻名,目前正在研究 CYB003(一种治疗重度抑郁症的药物)和治疗广泛性焦虑症的 CYB004。该公司成立于2019年,在多个国家开展业务,并将继续专注于推进其专有药物发现平台和治疗方案。
临床阶段的生物制药公司Cybin Inc. 宣布,其首席执行官道格·德赖斯代尔将出席布鲁姆·伯顿公司。2024年4月16日的医疗保健投资者大会。会议将在安大略省多伦多举行,德赖斯代尔的演讲定于美国东部时间下午 1:30 进行网络直播。Cybin 以开发针对心理健康状况的创新迷幻治疗方案而闻名,目前正在研究 CYB003(一种治疗重度抑郁症的药物)和治疗广泛性焦虑症的 CYB004。该公司成立于2019年,在多个国家开展业务,并将继续专注于推进其专有药物发现平台和治疗方案。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息